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over the time horizon of a patient’s lifetime were estimated at 20285, 144194, 299279, 
251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and 
CinnoVex, respectively. As a result, the incremental cost per QALY for patients 
receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 
and 1010429 USD, respectively, when compared with symptom management. The 
results were sensitive to changes in time horizon, disease progression and drug 
costs. ConClusions: DMDs in RRMS patients is associated with increased benefits 
compared with symptom management, albeit at higher costs. Because patients 
receiving Avonex incurred slightly higher QALYs than patients receiving other 
DMDs, treatment with Avonex dominate other DMDs in Iran.
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objeCtives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients’ quality of life. The aim of this study is to conduct a cost-utility 
analysis of natalizumab (Tysabri®) versus interferon beta-1a 44 mcg (Rebif®) – a 
commonly prescribed 1st line disease modifying therapy – in rapidly evolving severe 
relapsing-remitting MS patients from the Brazilian Public Healthcare System (SUS) 
perspective. Methods: A Markov model with 20-year time horizon with health 
states based on Expanded Disability Status Scale (EDSS) and disease relapses 
was developed. Since there are no published data evaluating long-term course 
specifically in RESRRMS, it was assumed transition probabilities on EDSS states were 
based on natural history studies in unselected RRMS patients, and relapse prob-
abilities based on a post-hoc analysis of the placebo patients on pivotal natalizumab 
AFFIRM trial. In each monthly cycle, patients can discontinue treatment, remain 
stable, progress to higher EDSS state, experience progressive multifocal leukoen-
cephalopathy (PML) or die. For natalizumab, we assumed efficacy data on disabil-
ity progression and relapse from AFFIRM trial and for interferon beta-1a 44 mcg 
we assumed efficacy data on disability progression and relapse from pivotal trial 
PRISMS. Patients with EDSS score ≥ 7.5 receive best supportive care. Resource use 
and costs were validated by an expert panel and valued using Brazilian public offi-
cial lists (DATASUS and BPS). Costs and outcomes were discounted (5%). Probabilistic 
sensitivity analyses covered variability in efficacy and costs. Results: The use of 
natalizumab was associated with slower EDSS progression and reduced relapse 
burden. The quality-adjusted life years obtained with natalizumab and interferon 
beta-1a 44 mcg were 9.27 and 8.75, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus interferon beta-1a 
44 mcg. ConClusions: For a patient with HARRMS, the model shows that natali-
zumab was dominant when compared to interferon beta-1a 44 mcg in the Brazilian 
Public Healthcare System.
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objeCtives: To estimate the costs associated with health and social care resource 
use in a UK cohort of people with progressive multiple sclerosis (MS). Methods: 
Health and social care resource use data were collected prospectively over 33 
months from a cohort of 458 patients with progressive MS enrolled in a UK clinical 
trial (the CUPID Trial). Resource use data are used in combination with unit costs 
(2011 costs) from published UK national sources, and estimates of costs/prices 
where required. Costs for informal (unpaid) care are estimated using equivalent 
hourly home care rates for UK NHS and social care services. Data are presented 
over the 33-month period of follow, and also to allow comparison with other 
studies, against an estimated 6-monthly cost. Regression analyses were used to 
explore the impact on cost estimates from explanatory variables. Results: The 
main component of resource us and costs was informal care provided by friends 
and family, accounting for over 84% of the estimated costs over time. Excluding 
informal care, the most important cost items, within the remaining sub-total of 
costs, were social care (52%), health care services (23%), medications (10%), adapta-
tions (8%), and hospitalisations (6%). From a Payer perspective, the estimated mean 
six-monthly costs of health and social care were £927, but from a broader perspec-
tive the estimated six-monthly cost was £10,737, when private and patient costs 
were included. Regression analyses identified disease severity, as characterised by 
the EDSS, as the main explanatory driver of cost estimates. ConClusions: This 
study presents new information to inform on the impact of progressive multiple 
sclerosis to add to the currently sparse evidence base. Data suggest that costs are 
considerable and fall mainly on patients and carers. The findings also confirm 
the central role of disability status in predicting overall costs associated with the 
impact of progressive MS.
NeUrologiCAl DisorDers – Patient-reported outcomes & Patient Preference 
studies
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objeCtives: To appraise the literature relating adherence and other patients’ 
reported outcomes (PROs) to Multiple Sclerosis (MS) costs. Methods: Electronic 
databases [MedLine/PubMed, Google Scholar, Congress proceedings] were searched 
to identify publications analyzing MS costs related to adherence, persistence, sat-
times GDP per capita (43,000 EUR) in the Czech Republic. Results: Over a 20 year 
time-horizon, add-on lacosamide generated 11.47 QALYs and costs 33,439 EUR (per 
patient), whereas standard AEDs alone provided 11.09 QALYs and costs 22,916 EUR 
(per patient), respectively. The base-case ICER was calculated as 27,692 EUR/QALY. 
Based on the PSA and its cost-effectiveness acceptability curve (CEAC) we calculated 
that add-on lacosamide has a probability of cost-effectiveness at 43,000 EUR per 
QALY gained of 80.2% compared to standard AEDs alone. ConClusions: Based 
on data from clinical practice lacosamide as add-on treatment in patients with 
partial-onset seizures is cost-effective under the WTP threshold implicitly applied 
in the Czech Republic.
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objeCtives: Carbamazepine (CBZ) is a widely-used, first-line treatment in epilepsy. 
However, CBZ is associated with hypersensitivity adverse drug reactions (ADRs) 
ranging from mild rash such as maculopapular exanthema, to hypersensitivity 
syndrome, Steven-Johnson syndrome and toxic epidermal necrolysis (TEN). TEN is 
associated with a mortality rate of up to 30%. The presence of the HLA-A*3101 allele 
is associated with an increased risk of CBZ-induced hypersensitivity reactions [OR 
9.1, 95% CI, 4.0 to 20.7]. HLA-A*3101 is present in 2% - 5% of populations of Northern 
European descent. We aim to investigate the cost effectiveness of pharmacoge-
netic testing for HLA-A*3101prior to initiation of CBZ treatment in patient with 
epilepsy. Patients testing positive for the allele are prescribed an alternative antie-
pileptic drug, lamotrigine. Methods: A decision analytic model was developed to 
represent the first three months post initiation of anti-epileptic drug, to cover the 
period when the majority of severe ADRs manifest. A Markov model (cycle length 
1 year) was used to simulate costs (from the perspective of the NHS in the UK) and 
utilities incurred in subsequent years. This enables modelling of costs and disutili-
ties from long term sequelae of severe ADRs as well as the effectiveness of treatment 
in terms of remission of seizures. Transition probabilities, costs and utilities were 
sourced from patient level data from the SANAD trial [Lancet 369(9566):1000-15] 
and relevant literature. Results: Compared with no pharmacogenetic testing, and 
prescribing CBZ for all patients, the test results in an incremental cost effective-
ness ratio of £26,684 per QALY gained. The probability that testing is cost-effective 
at a threshold of £30,000 per QALY is 0.55, and the cost of preventing a single ADR 
is £35962. ConClusions: Pharmacogenetic testing for HLA-A*3101 prior to treat-
ment with CBZ might be cost-effective for populations of North European descent.
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objeCtives: Botulinum toxin type A (BoNT-A) is considered one of the treatments 
of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy 
(CP) patients, two years of age or older by decreasing hyperactivity and increasing 
muscle tone in patients. The aim was to compare the cost of Botox® (Allergan) and 
Dysport® (Ipsen), considering the administered dose per weight (U/kg) in child 
patients with equinus foot CP related. Methods: We performed an observational, 
longitudinal and retrospective study with data from clinical records from December 
1995 to October 2012. Records included patients younger than 18 years old with 
spasticity treated with BoNT-A at the Pediatric Neurology Service of the Hospital of 
La Paz (Madrid), with recorded birth and visit dates, weight and dose by muscle. Cost 
analysis only evaluated four muscle groups (pronator teres, adductor, semitendi-
nosus and triceps surae) including only direct costs (drug and visit costs). We used 
bootstrap as sensitivity analysis to assess the robustness of results. Costs were in 
euros 2013. Results: A total of 895 patients treated with BoNT-A for spasticity (543 
treated with Botox®, 292 with Dysport® and 60 with both) were included. Baseline 
characteristics and follow-up were similar in both groups. Patients had an average 
dose infiltrated per visit of 5.44 U/kg (SD 2.17) for Botox® and 14.73 U/kg (SD 5.26) 
for Dysport®, and average yearly visits of 3.71 for Botox® and 3.46 for Dysport®. The 
annual total cost per patient was 850 € for Botox® and 636 € for Dysport®. Of these 
total costs, annual visit costs of 362 € for Botox® and 347 € for Dysport®, and annual 
drug costs were 488 € for Botox® and 289 € for Dysport®. ConClusions: Based on 
the real-world management of pediatric spasticity patients with BoNT-A observed 
in our study, Dysport® could reduce annual total costs per patient.
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objeCtives: Disease-modifying drugs (DMDs) are a significant expenditure for 
treating multiple sclerosis. However, assessment of the cost-utility of DMDs com-
pared with symptom management in the presence of long-term data has been lim-
ited. To assess the lifetime cost-utility from the Iranian health care perspectives of 4 
disease-modifying drugs relative to symptom management alone in patients with 
relapsing-remitting multiple sclerosis using evidence from long-term published 
studies. Methods: A Markov model was developed with patients transitioning 
through health states based on Kurtzke expanded disability status scale (EDSS). 
Patient costs included drug costs, other medical and lost worker productivity costs. 
Patient quality of life was considered in the form of utilities. Costs were valued in 
2011 USD, and costs were discounted at 7.2%per annum. Various parameters and 
assumptions were tested in sensitivity analyses. Results: Total costs per patient 
